Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

Rolland, Benjamin; Trojak, Benoît; Nourredine, Mikaïl; Bachellier, Jérôme; Chappuy, Mathieu; Bendimerad, Patrick; Kosim, Margaux; Hjelmström, Peter; Meroueh, Fadi; Nubukpo, Philippe; Brousse, Georges

doi:10.1016/j.drugalcdep.2020.108492

Cited by 14 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the recent AMBRE study conducted in France in 366 treatment-seeking subjects with OUD, approximately one-third of the recruited sample consisted of incarcerated people. 25 This study found no difference in the number of people interested in being treated with XR-BUP between incarcerated and non-incarcerated participants. Nonetheless, respondents that reported experiencing situations in which taking their MOUD was impractical were significantly more interested in XR-BUP.…”

Section: Introductionmentioning

confidence: 55%

“… 4 , 24 However, because some people with OUD were concerned about the concept of XR-BUP and more precisely with respect to a possible limitation of freedom and coercive treatment, 12 , 13 it was important to address whether incarcerated people with OUD were ready to try XR-BUP or reluctant to receive it, and what could be the factors of interest and the expectations about these new formulations. In the main results of the AMBRE survey, which were previously published in the parent study, 25 it was found that a majority of the participants was interested in the principle of XR-BUP, and that the average level of interest was similar in incarcerated and non-incarcerated interviewees. However, we did not explore whether the factors of interest and expectations about XR-BUP were different.…”

Section: Discussionmentioning

confidence: 77%

See 1 more Smart Citation

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder

Chappuy¹,

Meroueh²,

Trojak³

et al. 2021

PPA

Self Cite

View full text Add to dashboard Cite

Purpose Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous findings have shown that incarcerated subjects were not less interested in XR-BUP than non-incarcerated subjects. However, no study has ever investigated whether the factors of interest in XR-BUP were similar in incarcerated and non-incarcerated populations. Patients and Methods We carried out post-hoc analyses using data from the “AMBRE” survey, which was conducted among 366 individuals with OUD, that were recruited in 68 French addiction settings, including six prison medical centers. The reasons for interest in XR-BUP were compared between incarcerated and non-incarcerated interviewees, using logistic regressions models, which provided raw and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI). Adjustment variables were gender, age category, level of education, and type of current medication for OUD, respectively. Results Data from 317 participants (ie, 221 non-incarcerated, and 96 incarcerated individuals) were included in the analyses. Adjusted comparisons found that “no longer taking a daily treatment” (aOR= 2.91; 95% CI= 1.21–6.98) and “having a more discreet medication” (aOR= 1.76; 95% CI= 1.01–3.10) were reasons that appealed more to incarcerated participants than to non-incarcerated ones. On the other hand, the potential reduction of withdrawal symptoms (aOR= 0.54; 95% CI= 0.29–0.99) or the risk of misuse (aOR= 0.56; 95% CI= 0.34–0.94) associated with XR-BUP treatment were considered more important by non-incarcerated individuals than by incarcerated ones. Conclusion Incarcerated interviewees were interested in XR-BUP for different reasons than those outside prison. In particular, incarcerated patients were more interested in practicability and discretion features, and less in improving recovery or reducing misuse than non-incarcerated patients.

show abstract

Section: Introductionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 77%

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder

Chappuy¹,

Meroueh²,

Trojak³

et al. 2021

PPA

Self Cite

View full text Add to dashboard Cite

show abstract

“…These data are in agreement with those reported in other studies about the perception of PRB by patients with OUD. In a French study on 357 patients, the mean interest in PRB was 6.2 out of 10 [30]. In another study conducted in Australia, 68% of the total sample (n = 402) thought that PRB would be a good treatment option for OUD, and 84.86% of patients who declared the preference on frequency of administration said that they would prefer the monthly administration [31].…”

Section: Discussionmentioning

confidence: 99%

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

et al. 2021

View full text Add to dashboard Cite

Aim: The aim of the study was to assess the acceptance of patients with opioid use disorder (OUD) to switching their opioid dependence treatment (ODT) for a prolonged-release buprenorphine (PRB) injection according to their prior ODT (buprenorphine/naloxone [B/N] or methadone). Methods: This was an observational, retrospective/cross-sectional, multicentre study of adult patients diagnosed with OUD on ODT. Data collected from diaries were analysed to know their interest and opinion on PRB. Questions with fixed response options were included, and several Likert scales were used. Results: A total of 98 patients were enrolled (B/N: 50.0%, methadone: 50.0%). The mean age was 46.9 ± 8.43 years and 79.6% were males. PRB was similarly perceived by both groups in most variables analysed, receiving a mean score of 7.2/10 (B/N: 7.4, methadone: 7.0; p = 0.520), and approximately 65% of patients said they were willing to switch to PRB (B/N: 63.3%, methadone: 65.3%; p = 0.833). Of these, a higher percentage in the B/N group considered that switching would be easy/very easy (B/N: 90.3%, methadone: 46.9%; p < 0.001) and that they would start PRB when available (B/N: 64.5%, methadone: 34.3%; p = 0.005). More than 90% would prefer the monthly injection (B/N: 93.6%, methadone: 100%; p = 0.514). One-third of patients in both groups were unsure/would not switch their ODT to PRB (B/N: 36.7%, methadone: 34.7%; p = 0.833). The main reason was administration by injection. Conclusion: Two-thirds of patients would switch their treatment for PRB, and most patients on B/N considered that switching would be easy. PRB could be a suitable alternative for OUD management.

show abstract

“…Por otra parte, este proyecto tiene una serie de limitaciones que se deben tener en cuenta. En el estudio se ha empleado un cuestionario diseñado de forma específica para este estudio basado en el publicado por Rolland et al (2021). No se consideraron otros cuestionarios validados como el de Pérez de los Cobos et al ( 2020) debido a que es una población muy compleja y entendiendo por parte de los autores que un cuestionario con diseño específico podría captar mejor la información de estudio.…”

Section: Discussionunclassified

Satisfacción y experiencia de pacientes en tratamiento con sustitutivos opioides en España. Estudio PREDEPO

Pastor¹,

Muñoz²,

Oraá³

et al. 2021

Adicciones

View full text Add to dashboard Cite

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone

Cited by 14 publications

References 16 publications

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder

Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study

Satisfacción y experiencia de pacientes en tratamiento con sustitutivos opioides en España. Estudio PREDEPO

Contact Info

Product

Resources

About